Trials / Unknown
UnknownNCT05444322
A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- He Huang · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to explore the safety and tolerability of RD14-01 for patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma. And to evaluate the efficacy and pharmacokinetics of RD14-01 in patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RD14-01 cell infusion | Autologous CAR T cells |
Timeline
- Start date
- 2022-07-05
- Primary completion
- 2024-07-10
- Completion
- 2025-07-10
- First posted
- 2022-07-05
- Last updated
- 2022-07-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05444322. Inclusion in this directory is not an endorsement.